Articles

The combination of umbralisib and ublituximab, referred to as U2, was well-tolerated and significantly improved progression-free survival when compared with standard of care in patients with both treatment-naïve and relapsed or refractory chronic lymphocytic leukemia (CLL). Read More ›

Overall survival hazard ratios based on adjusted simulated treatment comparisons numerically, but not statistically, favored glasdegib plus low-dose cytarabine (LDAC) over venetoclax plus LDAC. Read More ›

The informCLL registry of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) can help to resolve knowledge gaps that may be identified in the evaluation and treatment of patients with CLL/SLL. Read More ›

As salvage therapy in younger patients with relapsed/refractory acute myeloid leukemia (AML), the efficacy of 10-day decitabine + venetoclax is comparable to intensive chemotherapy regimens and is an appropriate bridge to allogeneic stem-cell transplantation. Read More ›

Primary results from the CAPTIVATE study demonstrate that fixed-duration treatment with ibrutinib plus venetoclax offers treatment-free remission for patients with previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Read More ›

Across multiple acute myeloid leukemia (AML) subgroups, venetoclax + FLAG-IDA was effective, elicited deep responses, and had an acceptable safety profile, representing an attractive option as a bridge to allo-SCT for adverse-risk, newly diagnosed, and relapsed/refractory (R/R) AML patients. Read More ›

Combination ibrutinib plus venetoclax treatment results in sustained response in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). This response is sustained despite planned discontinuation in patients who had achieved minimal residual disease. Read More ›

In older patients with de novo acute myeloid leukemia, the combination of selinexor with standard induction and consolidation therapy appears highly active. Read More ›

Individual clonal growth rates can be used to estimate the minimal residual disease doubling time after fixed-duration treatment. Clonal growth rates were lower after treatment with venetoclax-obinutuzumab when compared with chlorambucil-obinutuzumab. Read More ›

In patients with newly diagnosed IDH2^mut acute myeloid leukemia (AML), treatment with enasidenib was associated with low early death and high complete response and complete response with incomplete hematologic recovery rates and yielded durable remission. Read More ›